Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB)

Last week, we had the privilege of hosting the Scientific Advisory Board (SAB) Meeting right here at Biozentrum, University of Basel. It was a moment to reflect on a year of #progress, #research, and collective effort in #advancing multiple sclerosis (#MS) research. A heartfelt thank you to our dedicated speakers and the entire Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) team who showcased their work through engaging presentations. The feedback from our Advisory Board was immensely positive, emphasizing their encouragement for the strides we've made in translational research. What sets #RC2NB apart is the unique research environment in #Basel. Here, a powerful combination of well-defined patient cohorts, a strong clinical trial framework, and advanced tools for clinical phenotyping converge seamlessly. Add to that our state-of-the-art neuroimaging techniques, biomarker analysis, and precise immunological monitoring of therapies, and you have a setting primed for advancements. This meeting reinforced what we already knew: impactful research thrives where expertise, technology, and dedication meet. Thank you to everyone who participated, contributed, and made this milestone possible. Looking forward to more research and continued innovation in the year ahead! Cristina Granziera, Ludwig Kappos, Jens Kuhle, Tobias Derfuss, PD Dr. med. Marcus D`Souza, Johanna Oechtering, Anne-Katrin Pröbstel, Lars G. Hemkens, Silvan Pless, Matthias Mehling, Ilaria Callegari, Bebeka Cosandey, Lea Hanl, Philipp Limberg, Perrine Janiaud, Kathleen Herrgott, Johannes Lorscheider, Martina Greselin, Daniel Reich, Xavier Montalban, Pascal Benkert, Amit Khanna, Maria Pia Sormani, Björn Tackenberg, University of Basel, University Hospital Basel, Department of Biomedicine, Departement Klinische Forschung, Universität Basel. #MSResearch #RC2NB #ScientificAdvisoryBoard #BaselResearch

Reminder: Personalized Health: Insights from the Upper Rhine – This Thursday in Basel! 📅 Date: November 7th 📍 Location: Biozentrum, University of Basel Dive into the forefront of personalized healthcare powered by data! This event is your chance to gain unique insights and connect with experts. Here’s what’s on the agenda: 🎤 Clinnova: A Cross-Border Data Platform for Autoimmune Treatment – Prof. Cristina Granziera, Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) 🎤 Behind the Screens: Data Architecture at the University Hospital Basel – Dr. Bram Stieltjes, USB 🎤 Data Revolution: Harnessing FAIR Principles – Dr. Sabine Österle, Swiss Personalized Health Network (SPHN) 🎤 OncoGenomX: Data-Driven Precision for Future Healthcare – Dr. Wolfgang Hackl 🎤 AI & Imaging: Innovative Drug Screening Platform – Dr. Shan Yang, University Hospital Basel Get ready for an inspiring day of insights and collaboration. We look forward to seeing you there! Eucor – The European Campus - University of Basel - University of Strasbourg - Université de Haute-Alsace - UHA - Karlsruhe Institute of Technology (KIT) - The University of Freiburg - Albert-Ludwigs-Universität Freiburg (Albert Ludwig University of Freiburg)- Department of Biomedicine - Departement Klinische Forschung, Universität Basel- Department of Biomedical Engineering | University of Basel - Innovation Office University of Basel - EURIdoc PhD Programme - Neurex - IGBMC -IGBMC Students and Post-docs Board (SPB) - University Hospital Basel

We’re more than 1,000 strong now - let's celebrate!!! Thank you to each and every one of you for being part of the Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) #community. We've grown exponentially this past year, and reaching this milestone wouldn’t be possible without your incredible support. At RC2NB, we’re proud to be a growing #hub where #science, #collaboration, and #healthcare #innovation intersect. Together, we’re building a space that encourages #teaching, fosters state-of-the-art #research, and drives positive #change for patients. Let’s keep pushing forward science and healthcare, united in our #mission to enhance patients' #lives. Thank you for being with us on this #journey. Here’s to more #connections, more collaboration, and many more #milestones to come. Ludwig Kappos Cristina Granziera Dr Bebeka Gjoksi Cosandey University of Basel University Hospital Basel Department of Biomedicine Departement Klinische Forschung, Universität Basel #RC2NB #1Kfollowers #scienceandhealthcare #researchcommunity #milestone

Have you heard about Federated Learning? It’s transforming MS care - right from Basel! We’re excited to announce the latest publication from Clinnova. In this cross-border initiative, Dr.Bram Stieltjes and his team lead the Data Architecture, with Prof. Cristina Granziera spearheading Clinnova’s overall efforts in Switzerland. https://lnkd.in/eCtid5pA #Clinnova, uniting Switzerland, France, Germany, and Luxembourg, is pushing the boundaries of precision medicine by advancing data federation, standardization, and interoperability across Europe, and Basel is at the core of this mission. So, what’s Federated Learning (FL)? It’s a powerful AI approach that allows institutions to collaboratively develop models while keeping sensitive data secure at each location. This approach is transformative for complex diseases like multiple sclerosis (MS), enabling us to create predictive models that detect disease progression, optimize treatment pathways, and validate digital biomarkers without compromising patient privacy. Our new publication details Clinnova’s first #federatedlearning proof of concept (POC) for #MS. This POC uses FL for #MRI image segmentation in MS, a breakthrough that serves as a foundation for future AI-driven #healthcare advancements. Clinnova’s work also spans inflammatory bowel disease and rheumatoid diseases, with plans for federated biobanking and a digital health innovation platform, bringing data-driven care to the forefront. Dive into the full publication to discover how Federated Learning, driven by our #Basel team, is shaping a new era of secure, high-quality data sharing and collaboration for MS and beyond! https://lnkd.in/eCtid5pA Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) University of Basel University Hospital Basel Luxembourg Institute of Health Dr Bebeka Gjoksi Cosandey Siri Leemann, PhD, Amandine Bovay, Laura Leydinger John King, Tanja Stoll Basel Area Business & Innovation Neurex Eucor – The European Campus Niklas Bienbeck Department of Biomedical Engineering | University of Basel Department of Biomedicine Eucor – The European Campus

Hey #MS community!!! Have you seen the latest #media coverage of blood markers #sGFAP and #sNfL as biomarkers for Multiple Sclerosis disease activity featuring none other than Jens Kuhle and the incredible work of the Swiss MS Cohort (#SMSC). These markers are helping us better predict MS progression and personalize treatments for patients - truly a game changer. Check out the Departement Klinische Forschung, Universität Basel full coverage for an in-depth look at how this research is pushing the boundaries of precision medicine in MS here: https://lnkd.in/e5qGZe6B Full scientific article: https://lnkd.in/eE_66adV #MSresearch #biomarkers #sGFAP #sNfL #neuroscience #MScommunity #RC2NB University of Basel University Hospital Basel Department of Biomedicine Departement Klinische Forschung, Universität Basel Neurex ECTRIMS

Thrilled to announce our latest publication on Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis. Our research highlights the potential of serum GFAP and NfL as biomarkers prognosticating future risk of progression independent of relapse activity (PIRA) in MS. I’m incredibly grateful to my co-authors, Prof. Jens Kuhle team, Pascal Benkert, Eline Willemse, Swiss MS cohort, collaborators, and everyone involved in this project for their dedication and hard work. This is an exciting step forward to disentangle MS insidious progression, clinical trials and personalised treatment of people with MS. #MSResearch #SwissMScohort #MultipleSclerosis #Biomarkers #GFAP #NfL #ScienceBreakthroughs #PIRA #RC2NB #UniversitätspitaBasel #UniversityofBasel 👉check out the full paper here:

🚨 𝐍𝐞𝐰 𝐒𝐭𝐮𝐝𝐲 🚨 Released by Research Group of Prof. Jens Kuhle (Departement Klinische Forschung, Universität Basel / Department of Biomedicine / Universitätsspital Basel (USB) / Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB)) on Multiple Sclerosis (MS), examining two important biomarkers: 𝐬𝐞𝐫𝐮𝐦 𝐠𝐥𝐢𝐚𝐥 𝐟𝐢𝐛𝐫𝐢𝐥𝐥𝐚𝐫𝐲 𝐚𝐜𝐢𝐝𝐢𝐜 𝐩𝐫𝐨𝐭𝐞𝐢𝐧 (𝐬𝐆𝐅𝐀𝐏) and 𝐬𝐞𝐫𝐮𝐦 𝐧𝐞𝐮𝐫𝐨𝐟𝐢𝐥𝐚𝐦𝐞𝐧𝐭 𝐥𝐢𝐠𝐡𝐭 𝐜𝐡𝐚𝐢𝐧 (𝐬𝐍𝐟𝐋). 🔑 𝐊𝐞𝐲 𝐅𝐢𝐧𝐝𝐢𝐧𝐠𝐬: - 𝐬𝐆𝐅𝐀𝐏 serves as a marker for disease progression independent of relapses. High levels after one year of therapy indicate a 1.8x higher risk of disease progression (PIRA). - 𝐬𝐆𝐅𝐀𝐏 and 𝐬𝐍𝐟𝐋 measure different aspects of MS: while sNfL decreases in non-progressing patients, sGFAP increases on the group levels under B cell depleting therapy with an even further elevation in those experiencing PIRA. - 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐢𝐦𝐩𝐚𝐜𝐭: sGFAP appears to help identify patients at higher risk for disease progression, making clinical trials more efficient and potentially guiding individual treatment decisions in combination with sNfL. These insights could improve MS treatment by providing better tools to monitor disease activity, design trials more efficiently and tailor therapies more effectively. 👉 Read more: https://lnkd.in/eZ9Pg2H2 Universität Basel #Research #MultipleSclerosis #Neurology #Biomarkers #ClinicalTrials

🌟 Catch the Highlights of #ECTRIMS2024 on Our Platform! Enrich your knowledge with our on-demand sessions from ECTRIMS 2024, available on our congress platform until 31 January 2025. Dive into the most popular sessions, including: 🔹 New diagnostic criteria 🔹 Discontinuation and de-escalation treatment in #MS 🔹 The future of new therapies in MS Join us to stay ahead in the evolving world of #MultipleSclerosis treatments and research. Visit our platform today 👉 https://bit.ly/3AVrdPK Photo credit: Bartosch Salmanski Copyright © ECTRIMS 2024. All rights reserved.

🚨 New Research Alert 🚨 https://lnkd.in/e4EpWeRz A post-hoc analysis of data from 13 clinical trials, including 6155 patients treated with OCR, revealed key insights on infection risks in patients with multiple sclerosis (MS). Over a median treatment period of 3.7 years, 6.8% of patients experienced serious infections (SIs). The most common serious infections were respiratory, urinary, abdominal, gastrointestinal, and skin infections. Most cases (~90%) resolved, and treatment continued in over 80% of patients. Significant risk factors for SIs included the presence of comorbidities, high EDSS scores, and recent relapse activity, while time on OCR was not significantly associated with an increased risk of infections. The findings suggest that continuous treatment with OCR shows a manageable infection profile, and addressing modifiable risk factors may further reduce infection risks. We would like to congratulate the entire team for this research paper , and a special shout-out to our very own Prof. Ludwig Kappos and Prof. Tobias Derfuss from Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) for their contributions to this study! University of Basel University Hospital Basel Departement Klinische Forschung, Universität Basel

Hot off the press! We are thrilled to announce the publication of our article, "Advanced MRI Measures of Myelin and Axon Volume Identify Repair in Multiple Sclerosis," in the @Annals of Neurology. This study utilizes advanced #MRI techniques to examine the repair and damage processes in multiple sclerosis (MS) lesions. The research involved the analysis of 128 MS patients and 72 healthy controls, revealing that both repair and damage processes occur across the disease spectrum. Importantly, the frequency of repair lesions was found to be correlated with lower disability and neuroaxonal damage, underscoring the potential of MRI in monitoring lesion activity and guiding personalized treatment strategies. This work underscores the potential of MRI and AI-driven analysis in tracking lesion changes, which could lead to more personalized MS treatments. A big shoutout to the entire team for their innovative contributions, especially Gretel Sanabria Diaz and Cristina Granziera, for their exceptional efforts in advancing #MSresearch. Access the full article here: https://lnkd.in/eMurKifC #MultipleSclerosis #Neuroimaging #Research #AnnalsOfNeurology #RC2NB University of Basel University Hospital Basel Departement Klinische Forschung, Universität Basel Department of Biomedicine Department of Biomedical Engineering | University of Basel